Developing innovative treatments designed to improve the everyday lives of women and men
Driving Innovative Research
We aim to develop a targeted approach for diseases of high unmet medical need. Our team is committed to bringing much-needed attention and innovation to women’s health and prostate cancer.
– Lynn Seely, MD, President and Chief Executive Officer
For too long, patients have suffered in the shadows. We are bringing this issue to the light and fighting for a brighter future."
25 Nov 2019
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
19 Nov 2019
Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
18 Nov 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
12 Nov 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019